Alcon AG vs Campbell Soup Co. — how do they compare? Alcon AG trades at $74.19 (market cap $36.44B), while Campbell Soup Co. trades at $22.79 (market cap $6.78B). The key difference: Alcon AG is far larger — about 5.4× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| ALC | CPB | |
|---|---|---|
Market Cap | $36.44B | $6.78B |
Sector | Health | Consumer Staples |
52-Week High | $90.12 | $34.03 |
52-Week Low | $62.02 | $20.00 |
Enterprise Value | $40.28B | $13.38B |
Dividend Yield | 0.48% | 6.87% |
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →